Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Evaluating the Safety and Immunogenicity of COVI-VAC as a Booster Dose in Previously Vaccinated Adults Against COVID-19

NCT05233826 is registered in ClinicalTrials.gov with Codagenix, Inc as lead sponsor.

NCT NCT05233826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Evaluating the Safety and Immunogenicity of COVI-VAC as a Booster Dose in Previously Vaccinated Adults Against COVID-19
Lead sponsor
Codagenix, Inc
Phase
Phase 1
Overall status
Completed
Start date
April 14, 2022
Completion date
December 22, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2